Insider Transactions in Q1 2026 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2026
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
876
-4.06%
|
$5,256
$6.88 P/Share
|
|
Jan 02
2026
|
Robert Renninger Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
297
-2.26%
|
$1,782
$6.88 P/Share
|
|
Jan 02
2026
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
2,586
-5.96%
|
$15,516
$6.88 P/Share
|
|
Jan 02
2026
|
Martin Javier San CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,644
-13.89%
|
$9,864
$6.88 P/Share
|
|
Jan 02
2026
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
876
-5.9%
|
$5,256
$6.88 P/Share
|